Arrowhead Pharmaceuticals, Inc. (ARWR) — Stock Score Summary

Arrowhead Pharmaceuticals, Inc. (ARWR) has a MoatMap StockRank of 68/100 based on Quality (46/100), Value (35/100), and Momentum (67/100) factor scores. The current signal is BUY. Arrowhead Pharmaceuticals is a clinical-stage biotechnology company. Its business model is characterized by high research and development costs, uncertain regulatory approvals, and dependence on a limited pipeline of products. It lacks a clear macro tailwind and does not fit the profile of a quality compounder.

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat diseases lacking adequate treatments, with a pipeline targeting genetic and acquired diseases. Its proprietary TRiM™ platform for targeted RNAi delivery provides a competitive edge in developing novel treatments, attracting significant pharma partnerships. The company is a cutting-edge biotechnology firm specializing in RNAi technology with high-growth potential.

Key Financial Metrics

Price$76.67
Market Cap$10.5B
P/E (Forward)-17.88
Price/Book17.80
Return on Equity-42.4%
Return on Invested Capital11.8%
Debt/Equity231.05
Gross Margin100.0%
Operating Margin-191.6%
Revenue Growth-86.4%
Free Cash Flow$-46M

Arrowhead Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Arrowhead Pharmaceuticals, Inc.’s (ARWR) StockRank?
MoatMap’s StockRank for Arrowhead Pharmaceuticals, Inc. (ARWR) is 68/100, with a Buy signal. It is a composite of Quality (46), Value (35), and Momentum (67) factor ranks across MoatMap’s 15,000+ stock universe.
Does Arrowhead Pharmaceuticals, Inc. have an economic moat?
Arrowhead Pharmaceuticals, Inc. (ARWR) has a Quality factor score of 46/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Arrowhead Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Arrowhead Pharmaceuticals, Inc. (ARWR) is Buy, based on a StockRank of 68/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Arrowhead Pharmaceuticals, Inc. in?
Arrowhead Pharmaceuticals, Inc. (ARWR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksARWR deep dive reportAI ChampionsHow we score stocksSense-check another stock